Does Marijuana Rescheduling Really Help Tilray's Stock?
The U.S. government's reclassification of medical cannabis from Schedule I to Schedule III primarily benefits U.S.-based cannabis operators through lower tax bills, not Canadian producer Tilray. While rescheduling may be a step toward legalization, it doesn't guarantee future reform and could take years to materialize. Investors should be cautious about overreacting to rescheduling news, as Tilray's stock has historically surged temporarily on cannabis reform announcements only to decline to new lows.